Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04231877
Title Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Washington

B-cell lymphoma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma


Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST